DCM
BOLT icon

DAFNA Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

DAFNA Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,000
Closed -$490K – 95
2021
Q4 		$490K Hold
5,000
– – 0.12% 82
2021
Q3 		$1.26M Hold
5,000
– – 0.34% 64
2021
Q2 		$1.55M Buy
+5,000
New +$2.03M 0.32% 59

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ESCM
Echo Street Capital Management New York $747M AUM 24.25% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

DAFNA Capital Management's BOLT Position: Q1 2022 in Review

DAFNA Capital Management sold out of Bolt Biotherapeutics (BOLT) in Q1 2022, closing a stake of 5,000 shares — an estimated $490K sold.

DAFNA Capital Management first reported a position in BOLT in Q2 2021 and held it in 3 quarters. The position peaked at $1.55M in Q2 2021. 65 funds tracked by Wall St. Rank hold BOLT as of Q1 2022.

  • DAFNA Capital Management reported no remaining Bolt Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • DAFNA Capital Management sold 5,000 Bolt Biotherapeutics shares in Q1 2022, an estimated $490K.
  • DAFNA Capital Management first reported a position in Bolt Biotherapeutics in Q2 2021 and held it in 3 quarters.
  • DAFNA Capital Management's Bolt Biotherapeutics position peaked at $1.55M in Q2 2021.
  • 65 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2022.

Based on DAFNA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.